Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 08, 2024 20:00 ET | Source: Io Therapeutics, Inc.

Io Therapeutics, Inc., announces presentation of data on induction of tumor growth inhibiting anti-cancer immune responses in multiple types of cancers by a IRX5010, a novel retinoic acid nuclear receptor agonist compound

Io Therapeutics, Inc presented studies in multiple cancers with its novel drug that inhibits tumor growth by promoting tumor infiltrating T-lymphocytes